Dopamine D2 and D3 binding in people at clinical high risk for schizophrenia, antipsychotic-naive patients and healthy controls while performing a cognitive tasks

Journal of Psychiatry and Neuroscience

Volumn 38, Issue 2, 2013, Pages 98-106

  Suridjan, Ivonne ^a   Rusjan, Pablo ^a   Addington, Jean ^b   Wilson, Alan A ^a,c   Houle, Sylvain ^a,c   Mizrahi, Romina ^a,c  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIS; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; NAXAGOLIDE; TRACER; DOPAMINE RECEPTOR STIMULATING AGENT; OXAZINE DERIVATIVE;

ADULT; ARTICLE; CAUDATE NUCLEUS; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; CORPUS STRIATUM; FEMALE; GLOBUS PALLIDUS; HIGH RISK PATIENT; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PSYCHOSIS; PUTAMEN; RECEPTOR BINDING; SCHIZOPHRENIA; SMOKING; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS; SUBSTANTIA NIGRA; THALAMUS; VOXEL BASED MORPHOMETRY; ADOLESCENT; BRAIN; CASE CONTROL STUDY; DIAGNOSTIC USE; METABOLISM; PHYSIOLOGY; PROCEDURES; SCINTISCANNING; YOUNG ADULT;

ADOLESCENT; ADULT; BRAIN; CASE-CONTROL STUDIES; COGNITION; DOPAMINE AGONISTS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; OXAZINES; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84874335378     PISSN: 11804882     EISSN: 14882434     Source Type: Journal    
DOI: 10.1503/jpn.110181     Document Type: Article

References (63)

1. Nordström AL, Farde L, Eriksson L, et al. No elevated D2 dopamine receptors in neuroleptic-naive schizophrenic patients revealed by positron emission tomography and [11C]N-methyl-spiperone. Psychiatry Res 1995;61:67-83.
2. Tune LE, Wong DF, Pearlson G, et al. Dopamine D2 receptor density estimates in schizophrenia: a positron emission tomography study with 11C-N-methylspiperone. Psychiatry Res 1993;49:219-37.
3. Hietala J, Syvalahti E, Vuorio K, et al. Striatal D2 dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography. Arch Gen Psychiatry 1994;51:116-23.
4. Kestler LP, Walker E, Vega EM. Dopamine receptors in the brains of schizophrenia patients: a meta-analysis of the findings. Behav Pharmacol 2001;12:355-71.
5. Laruelle M. Imaging dopamine transmission in schizophrenia. A review and meta-analysis. Q J Nucl Med 1998;42:211-21.
6. Wong DF, Wagner HN Jr, Tune LE, et al. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science 1986;234:1558-63.
7. Seeman P, Weinshenker D, Quirion R, et al. Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis. Proc Natl Acad Sci U S A 2005;102:3513-8.
8. Wilson AA, McCormick P, Kapur S, et al. Radiosynthesis and evaluation of [11C]-(+)-4-propyl-3,4,4a,5,6,10b-hexahydro-2Hnaphtho[1,2-b][1,4]oxazin-9-ol as a potential radiotracer for in vivo imaging of the dopamine D2 high-affinity state with positron emission tomography. J Med Chem 2005;48:4153-60.
9. Willeit M, Ginovart N, Kapur S, et al. High-affinity states of human brain dopamine D2/3 receptors imaged by the agonist [11C] (+)-PHNO. Biol Psychiatry 2006;59:389-94.
10. Searle G, Beaver JD, Comley RA, et al. Imaging dopamine D3 receptors in the human brain with positron emission tomography, [11C]PHNO, and a selective D3 receptor antagonist. Biol Psychiatry 2010;68:392-9.
11. Tziortzi AC, Searle GE, Tzimopoulou S, et al. Imaging dopamine receptors in humans with [11C]-(+)-PHNO: dissection of D3 signal and anatomy. Neuroimage 2011;54:264-77.
12. Gallezot JD, Beaver JD, Gunn RN, et al. Affinity and selectivity of [(11) C]-(+)-PHNO for the D3 and D2 receptors in the rhesus monkey brain in vivo. Synapse 2012;66:489-500.
13. Rabiner EA, Slifstein M, Nobrega J, et al. In vivo quantification of regional dopamine-D3 receptor binding potential of (+)-PHNO: Studies in non-human primates and transgenic mice. Synapse 2009; 63:782-93.
14. Seeman P. Dopamine agonist radioligand binds to both D2High and D2Low receptors, explaining why alterations in D2High are not detected in human brain scans. Synapse 2012;66:88-93.
15. Seeman P, Ulpian C, Larsen RD, et al. Dopamine receptors labeled by PHNO. Synapse 1993;14:254-62.
16. Nobrega JN, Seeman P. Dopamine D2 receptors mapped in rat brain with [3H](+)PHNO. Synapse 1994;17:167-72.
17. McCormick PN, Kapur S, Seeman P, et al. Dopamine D2 receptor radiotracers [(11)C](+)-PHNO and [(3)H]raclopride are indistinguishably inhibited by D2 agonists and antagonists ex vivo. Nucl Med Biol 2008;35:11-7.
18. Shotbolt P, Tziortzi AC, Searle GE, et al. Within-subject comparison of [(11)C]-(+)-PHNO and [(11)C]raclopride sensitivity to acute amphetamine challenge in healthy humans. J Cereb Blood Flow Metab 2012;32:127-36.
19. Graff-Guerrero A, Mizrahi R, Agid O, et al. The dopamine D2 receptors in high-affinity state and D3 receptors in schizophrenia: a clinical [11C]-(+)-PHNO PET study. Neuropsychopharmacology 2009;34:1078-86.
20. Lappin JM, Reeves SJ, Mehta MA, et al. Dopamine release in the human striatum: motor and cognitive tasks revisited. J Cereb Blood Flow Metab 2009;29:554-64.
21. Abi-Dargham A, Gil R, Krystal J, et al. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 1998;155:761-7.
22. Laruelle M, Abi-Dargham A, Gil R, et al. Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol Psychiatry 1999;46:56-72.
23. Addington J, Cadenhead KS, Cannon TD, et al. North American Prodrome Longitudinal Study: a collaborative multisite approach to prodromal schizophrenia research. Schizophr Bull 2007;33:665-72.
24. Cannon TD, Cadenhead K, Cornblatt B, et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry 2008;65:28-37.
25. Mizrahi R, Addington J, Rusjan PM, et al. Increased stress-induced dopamine release in psychosis. Biol Psychiatry 2012;71:561-7.
26. Miller TJ, McGlashan TH, Rosen JL, et al. Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: preliminary evidence of interrater reliability and predictive validity. Am J Psychiatry 2002;159:863-5.
27. First MB, Splitzer RL, Miriam G, et al. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P). New York: Biometrics Research, New York State Psychiatric Institute; 2002.
28. Guy W. ECDEU assessment manual for psychopharmacology. Rockville (MD): U.S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976.
29. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76.
30. Pruessner JC, Champagne F, Meaney MJ, et al. Dopamine release in response to a psychological stress in humans and its relationship to early life maternal care: a positron emission tomography study using [11C]raclopride. J Neurosci 2004;24:2825-31.
31. Mawlawi O, Martinez D, Slifstein M, et al. Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D(2) receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab 2001;21:1034-57.
32. Martinez D, Slifstein M, Broft A, et al. Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab 2003;23:285-300.
33. Rusjan P, Mamo D, Ginovart N, et al. An automated method for the extraction of regional data from PET images. Psychiatry Res 2006;147:79-89.
34. Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage 1996;4:153-8.
35. Ginovart N, Willeit M, Rusjan P, et al. Positron emission tomography quantification of [11C]-(+)-PHNO binding in the human brain. J Cereb Blood Flow Metab 2007;27:857-71.
36. Gunn RN, Gunn SR, Turkheimer FE, et al. Positron emission tomography compartmental models: a basis pursuit strategy for kinetic modeling. J Cereb Blood Flow Metab 2002;22:1425-39.
37. Andreasen NC, Carson R, Diksic M, et al. Workshop on schizophrenia, PET, and dopamine D2 receptors in the human neostriatum. Schizophr Bull 1988;14:471-84.
38. Farde L, Wiesel FA, Stone-Elander S, et al. D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride. Arch Gen Psychiatry 1990;47:213-9.
39. Koepp MJ, Gunn RN, Lawrence AD, et al. Evidence for striatal dopamine release during a video game. Nature 1998;393:266-8.
40. Abi-Dargham A, Rodenhiser J, Printz D, et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci U S A 2000;97:8104-9.
41. Sibley DR, Mahan LC, Creese I. Dopamine receptor binding on intact cells. Absence of a high-affinity agonist-receptor binding state. Mol Pharmacol 1983;23:295-302.
42. Seeman P. Dopamine D2(High) receptors on intact cells. Synapse 2008;62:314-8.
43. Narendran R, Hwang DR, Slifstein M, et al. Measurement of the proportion of D2 receptors configured in state of high affinity for agonists in vivo: a positron emission tomography study using [11C]N-propyl-norapomorphine and [11C]raclopride in baboons. J Pharmacol Exp Ther 2005;315:80-90.
44. Ginovart N, Galineau L, Willeit M, et al. Binding characteristics and sensitivity to endogenous dopamine of [11C]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D2 receptors in vivo using positron emission tomography. J Neurochem 2006;97:1089-103.
45. Narendran R, Hwang DR, Slifstein M, et al. In vivo vulnerability to competition by endogenous dopamine: Comparison of the D2 receptor agonist radiotracer (-)-N-[11C]propyl-norapomorphine ([11C]NPA) with the D2 receptor antagonist radiotracer [11C] raclopride. Synapse 2004;52:188-208.
46. Seneca N, Finnema SJ, Farde L, et al. Effect of amphetamine on dopamine D2 receptor binding in nonhuman primate brain: a comparison of the agonist radioligand [11C]MNPA and antagonist [11C]raclopride. Synapse 2006;59:260-9.
47. Willeit M, Ginovart N, Graff A, et al. First human evidence of damphetamine induced displacement of a D(2/3) agonist radioligand: a [(11)C]-(+)-PHNO positron emission tomography study. Neuropsychopharmacology 2008;33:279-89.
48. Narendran R, Mason NS, Laymon CM, et al. A comparative evaluation of the dopamine D(2/3) agonist radiotracer [11C](-)-Npropyl-norapomorphine and antagonist [11C]raclopride to measure amphetamine-induced dopamine release in the human striatum. J Pharmacol Exp Ther 2010;333:533-539.
49. Finnema SJ, Halldin C, Bang-Andersen B, et al. Dopamine D(2/3) receptor occupancy of apomorphine in the nonhuman primate brain-a comparative PET study with [11C]raclopride and [11C]MNPA. Synapse 2009;63:378-89.
50. Farde L, Wiesel FA, Hall H, et al. No D2 receptor increase in PET study of schizophrenia. Arch Gen Psychiatry 1987;44:671-2.
51. Buchsbaum MS, Christian BT, Lehrer DS, et al. D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia. Schizophr Res 2006;85:232-44.
52. Kessler RM, Woodward ND, Riccardi P, et al. Dopamine D2 receptor levels in striatum, thalamus, substantia nigra, limbic regions, and cortex in schizophrenic subjects. Biol Psychiatry 2009;65:1024-31.
53. Yasuno F, Suhara T, Okubo Y, et al. Low dopamine d(2) receptor binding in subregions of the thalamus in schizophrenia. Am J Psychiatry 2004;161:1016-22.
54. Kegeles LS, Slifstein M, Xu X, et al. Striatal and extrastriatal dopamine D2/D3 receptors in schizophrenia evaluated with [18F]fallypride positron emission tomography. Biol Psychiatry 2010;68:634-41.
55. Glenthoj BY, Mackeprang T, Svarer C, et al. Frontal dopamine D(2/3) receptor binding in drug-naive first-episode schizophrenic patients correlates with positive psychotic symptoms and gender. Biol Psychiatry 2006;60:621-9.
56. Talvik M, Nordstrom AL, Olsson H, et al. Decreased thalamic D2/D3 receptor binding in drug-naive patients with schizophrenia: a PET study with [11C]FLB 457. Int J Neuropsychopharmacol 2003;6:361-70.
57. Hietala J, Syvalahti E, Vuorio K, et al. Presynaptic dopamine func-tion in striatum of neuroleptic-naive schizophrenic patients. Lancet 1995;346:1130-1.
58. Lindström LH, Gefvert O, Hagberg G, et al. Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(beta-11C) DOPA and PET. Biol Psychiatry 1999;46:681-8.
59. Reith J, Benkelfat C, Sherwin A, et al. Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc Natl Acad Sci U S A 1994;91:11651-4.
60. Dao-Castellana MH, Paillere-Martinot ML, Hantraye P, et al. Presynaptic dopaminergic function in the striatum of schizophrenic patients. Schizophr Res 1997;23:167-74.
61. Howes OD, Montgomery AJ, Asselin MC, et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry 2009;66:13-20.
62. Howes O, Bose S, Turkheimer F, et al. Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study. Mol Psychiatry 2011;16:885-6.
63. Mizrahi R, Agid O, Borlido C, et al. Effects of antipsychotics on D3 receptors: a clinical PET study in first episode antipsychotic naive patients with schizophrenia using [(11)C]-(+)-PHNO. Schizophr Res 2011;131:63-8.